my morning paper read just blew me away. zenbexus, a new targeted protein degrader (first of its kind!), got fda approval for multiple myeloma. in trials, 41% hit mrd-negative complete response, more than double the 21% in the control group. pretty incredible for this cancer.
FDA Grants Accelerated Approval to Zenbexus for Relapsed or Refractory Multiple Myeloma
The U.S. FDA has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have undergone at
www.facebook.com
August 17, 2026 at 2:01 AM
my morning paper read just blew me away. zenbexus, a new targeted protein degrader (first of its kind!), got fda approval for multiple myeloma. in trials, 41% hit mrd-negative complete response, more than double the 21% in the control group. pretty incredible for this cancer.
#MultipleMyeloma is an incurable blood cancer. This month a new class of drug has been FDA-approved to enter the therapeutic mix for adults under certain conditions - #Zenbexus (iberdomide) from Bristol-Myers Squibb, a specific targeted protein degrader, #CELMoD 🧪.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA grants accelerated approval to iberdomide with daratumumab and hya
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexa...
www.fda.gov
August 21, 2026 at 1:31 AM
#MultipleMyeloma is an incurable blood cancer. This month a new class of drug has been FDA-approved to enter the therapeutic mix for adults under certain conditions - #Zenbexus (iberdomide) from Bristol-Myers Squibb, a specific targeted protein degrader, #CELMoD 🧪.
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
📊 2026-09-27
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
September 27, 2026 at 3:47 AM
📊 2026-09-27
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
• Ocean Cleanup: Nearly Pristine Palmyra Atoll Reefs Offer a Restoration Blueprint — as California Vetoes New Plastic-Fund Spending Rules
• Cancer Breakthroughs: FDA Approves Zenbexus (Iberdomide), First-Ever CELMoD Therapy, in Historic First Oncology Approval Based…
🔗 watchboard.dev
【iberdomide併用、再発骨髄腫のMRD陰性完全奏効が2倍】
BMSのZENBEXUS（iberdomide）を、ダラツムマブとデキサメタゾンに足したZDd療法。再発・難治性多発性骨髄腫の第3相で、MRD陰性の完全奏効率が対照の2倍になった。米国では加速承認済み。今回は第3相成績の追加である。
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
stellanews.life/technology/1...
BMSのZENBEXUS（iberdomide）を、ダラツムマブとデキサメタゾンに足したZDd療法。再発・難治性多発性骨髄腫の第3相で、MRD陰性の完全奏効率が対照の2倍になった。米国では加速承認済み。今回は第3相成績の追加である。
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
stellanews.life/technology/1...
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
Bristol Myers Squibb社は第3相EXCALIBER-RRMM試験の結果を発表した。iberdomide＋ダラツムマブ併用療法は、対照群に比べMRD陰性完全奏効率を約2倍に高めた（41.1％対20.7％）。
stellanews.life
September 28, 2026 at 4:13 AM
【iberdomide併用、再発骨髄腫のMRD陰性完全奏効が2倍】
BMSのZENBEXUS（iberdomide）を、ダラツムマブとデキサメタゾンに足したZDd療法。再発・難治性多発性骨髄腫の第3相で、MRD陰性の完全奏効率が対照の2倍になった。米国では加速承認済み。今回は第3相成績の追加である。
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
stellanews.life/technology/1...
BMSのZENBEXUS（iberdomide）を、ダラツムマブとデキサメタゾンに足したZDd療法。再発・難治性多発性骨髄腫の第3相で、MRD陰性の完全奏効率が対照の2倍になった。米国では加速承認済み。今回は第3相成績の追加である。
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
stellanews.life/technology/1...
#CELMoD stands for "cereblon E3 ligase modulators". These are targeted protein degraders that use our cells' 'trash can' - the proteasome, to degrade & get rid of proteins with roles in driving malignancy. Exciting news for #MultipleMyeloma - #Zenbexus #iberdomide. 🧪
www.drugs.com/medical-answ...
www.drugs.com/medical-answ...
www.drugs.com
August 21, 2026 at 1:47 AM
#CELMoD stands for "cereblon E3 ligase modulators". These are targeted protein degraders that use our cells' 'trash can' - the proteasome, to degrade & get rid of proteins with roles in driving malignancy. Exciting news for #MultipleMyeloma - #Zenbexus #iberdomide. 🧪
www.drugs.com/medical-answ...
www.drugs.com/medical-answ...
Multiple myeloma that resists treatment used to leave few options. Now, FDA approved iberdomide, a new CELMoD drug. It more than doubled the rate of deep remission (MRD-negative complete response) to 41% vs. 21% for standard care in Phase 3. Big difference.
FDA Grants Accelerated Approval to Iberdomide for Relapsed/Refractory Multiple Myeloma
The FDA has given accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and dexamethasone for adults with multiple myeloma that has returned or is resistant to previous treatme
www.fda.gov
August 18, 2026 at 2:03 AM
Multiple myeloma that resists treatment used to leave few options. Now, FDA approved iberdomide, a new CELMoD drug. It more than doubled the rate of deep remission (MRD-negative complete response) to 41% vs. 21% for standard care in Phase 3. Big difference.
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma medcitynews.com/2026/08/bris...
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma - MedCity News
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for ...
medcitynews.com
August 15, 2026 at 12:12 PM
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma medcitynews.com/2026/08/bris...
Newest glue degrader nabs multiple myeloma approval
www.nature.com/articles/d41...
Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors
www.nature.com/articles/d41...
Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors
Newest glue degrader nabs multiple myeloma approval
Discover the world’s best science and medicine | Nature.com
www.nature.com
September 11, 2026 at 11:39 AM
Newest glue degrader nabs multiple myeloma approval
www.nature.com/articles/d41...
Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors
www.nature.com/articles/d41...
Iberdomide (Zenbexus; Bristol Myers Squibb) is an “important proof point” for targeted protein degradation, showing how new molecular glue degraders can improve on their predecessors
STAT+: PBMs agree to display TrumpRx drug prices www.statnews.com/2026/08/14/b...
PBMs agree to display TrumpRx drug prices
Bristol's Zenbexus wins accelerated approval, Novartis wins UK patent fight over Entresto, and more biotech news from The Readout
www.statnews.com
August 15, 2026 at 1:12 AM
STAT+: PBMs agree to display TrumpRx drug prices www.statnews.com/2026/08/14/b...
FDA grants accelerated approval to iberdomide combo in multiple myeloma
sohoinsider.com/news/fda-gra...
sohoinsider.com/news/fda-gra...
FDA grants accelerated approval to iberdomide combo in multiple myeloma
The US Food and Drug Administration has granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma…
sohoinsider.com
August 15, 2026 at 1:00 AM
FDA grants accelerated approval to iberdomide combo in multiple myeloma
sohoinsider.com/news/fda-gra...
sohoinsider.com/news/fda-gra...
FDA approves first-of-its-kind drug rusfertide for polycythemia vera
https://cancerletter.com/drugs-and-targets/20260911_10d/
https://cancerletter.com/drugs-and-targets/20260911_10d/
FDA grants accelerated approval to iberdomide combination for MM - The Cancer Letter
FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex
cancerletter.com
September 18, 2026 at 12:01 PM
FDA approves first-of-its-kind drug rusfertide for polycythemia vera
https://cancerletter.com/drugs-and-targets/20260911_10d/
https://cancerletter.com/drugs-and-targets/20260911_10d/
FDA grants accelerated approval to iberdomide combination for MM
https://cancerletter.com/drugs-and-targets/20260911_10a/
https://cancerletter.com/drugs-and-targets/20260911_10a/
FDA grants accelerated approval to iberdomide combination for MM - The Cancer Letter
FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex
cancerletter.com
September 13, 2026 at 1:00 AM
FDA grants accelerated approval to iberdomide combination for MM
https://cancerletter.com/drugs-and-targets/20260911_10a/
https://cancerletter.com/drugs-and-targets/20260911_10a/
The FDA cleared 3 blockbuster drugs in August — including one for a disease so rare most doctors never see it.
FDA Clears Multiple Blockbuster Drugs in August 2026, Including BMS's Zenbexus, Takeda's
https://tech-quire.com/articles/fda-august-2026-multiple-drug-approvals-zenbexus-orzeyful-pasatru/
FDA Clears Multiple Blockbuster Drugs in August 2026, Including BMS's Zenbexus, Takeda's
https://tech-quire.com/articles/fda-august-2026-multiple-drug-approvals-zenbexus-orzeyful-pasatru/
August 25, 2026 at 12:38 PM
The FDA cleared 3 blockbuster drugs in August — including one for a disease so rare most doctors never see it.
FDA Clears Multiple Blockbuster Drugs in August 2026, Including BMS's Zenbexus, Takeda's
https://tech-quire.com/articles/fda-august-2026-multiple-drug-approvals-zenbexus-orzeyful-pasatru/
FDA Clears Multiple Blockbuster Drugs in August 2026, Including BMS's Zenbexus, Takeda's
https://tech-quire.com/articles/fda-august-2026-multiple-drug-approvals-zenbexus-orzeyful-pasatru/
Breaking news: the @fda.gov approved iberdomide (Zenbexus) for adults with multiple myeloma who've had prior treatment. First therapy approved through a new accelerated approval method using bone marrow response data, building on early research we helped fund.
Learn more about this new therapy 👇
Learn more about this new therapy 👇
FDA Approves First-of-its-Kind Treatment for Multiple Myeloma | Blood Cancer United
“We continue to be encouraged by the sustained progress being made in myeloma research and remain hopeful that advances like this will lead to better outcomes for patients and families," said Lore Gru...
bcutd.org
August 22, 2026 at 11:23 PM
Breaking news: the @fda.gov approved iberdomide (Zenbexus) for adults with multiple myeloma who've had prior treatment. First therapy approved through a new accelerated approval method using bone marrow response data, building on early research we helped fund.
Learn more about this new therapy 👇
Learn more about this new therapy 👇
www.biopharmadive.com/news/bristol...
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.
www.biopharmadive.com
August 21, 2026 at 12:44 AM
www.biopharmadive.com/news/bristol...
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval#United_States#Multiple_Myeloma#Tinley_Park#Hematogenix#ZENBEXUS
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval
Hematogenix's MM MRD assay has played a crucial role in the FDA's accelerated approval of ZENBEXUS, the first CELMoD therapy for multiple myeloma.
third-news.com
August 19, 2026 at 12:48 PM
Hematogenix's Innovative Assay Paves Way for New Multiple Myeloma Treatment Approval#United_States#Multiple_Myeloma#Tinley_Park#Hematogenix#ZENBEXUS
STAT+: PBMs agree to display TrumpRx drug prices
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K....
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K....
STAT+: PBMs agree to display TrumpRx drug prices
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K. patent fight over Entresto. My son built a structurally sound bridge yesterday out of latticed twigs; it supported my weight and also his. It was a moment of great pride. Hire him, he’s 8. Bristol’s Zenbexus wins accelerated approval in multiple myeloma…
primereports.org
August 17, 2026 at 12:01 AM
STAT+: PBMs agree to display TrumpRx drug prices
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K....
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.K....
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
https://cancerletter.com/drugs-and-targets/20260814_11a/
https://cancerletter.com/drugs-and-targets/20260814_11a/
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma - The Cancer Letter
FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dex
cancerletter.com
August 16, 2026 at 1:00 AM
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
https://cancerletter.com/drugs-and-targets/20260814_11a/
https://cancerletter.com/drugs-and-targets/20260814_11a/
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple…
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple…
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple myeloma. The post Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma appeared first on MedCity News .
news-area.com
August 15, 2026 at 7:28 AM
Bristol Myers Squibb Protein Degrader Wins First-in-Class FDA Nod in Multiple Myeloma
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple…
Bristol Myers Squibb’s Zenbexus is the first FDA-approved drug in a new class of cancer drugs called CELMoDs. The pharma company is positioning this molecule as a successor to its legacy products for multiple…
FDA accelerates approval of the first-in-class CELMoD agent, Zenbexus, offering a new oral option for adults with relapsed or refractory multiple myeloma. https://www.empr.com/news/fda-approves-zenbexus-iberdomide-multiple-myeloma/
Zenbexus Granted Accelerated Approval in Relapsed or Refractory Multiple Myeloma
Accelerated FDA approval of the first-in-class CELMoD agent iberdomide (Zenbexus) offers a new oral option for adults with relapsed or refractory multiple myeloma.
www.empr.com
August 14, 2026 at 4:51 PM
FDA accelerates approval of the first-in-class CELMoD agent, Zenbexus, offering a new oral option for adults with relapsed or refractory multiple myeloma. https://www.empr.com/news/fda-approves-zenbexus-iberdomide-multiple-myeloma/
A new class of multiple myeloma treatment has arrived. The FDA has approved Zenbexus in combination therapy for previously treated patients, the first approved CELMoD protein degrader for multiple myeloma.
www.oncologynewscentral.com/drugs/info/f...
#MultipleMyeloma #BloodCancer #Cancer #TCSC
www.oncologynewscentral.com/drugs/info/f...
#MultipleMyeloma #BloodCancer #Cancer #TCSC
FDA Approves Iberdomide Plus Daratumumab and Dexamethasone for Multiple Myeloma
Learn about the FDA approval of iberdomide plus daratumumab and hyaluronidase-fihj and dexamethasone for treating multiple myeloma, offering new hope for patients with relapsed or refractory disease.
www.oncologynewscentral.com
August 15, 2026 at 7:56 AM
A new class of multiple myeloma treatment has arrived. The FDA has approved Zenbexus in combination therapy for previously treated patients, the first approved CELMoD protein degrader for multiple myeloma.
www.oncologynewscentral.com/drugs/info/f...
#MultipleMyeloma #BloodCancer #Cancer #TCSC
www.oncologynewscentral.com/drugs/info/f...
#MultipleMyeloma #BloodCancer #Cancer #TCSC
Fri news: Novo's Wegovy pill struggles to break through market share ceiling. Karyopharm as company faces potential default next month. BMS bags first approval for myeloma CELMoD Zenbexus. Novartis wins UK court battle over Entresto patent. —https://bit.ly/3JeBlY5
August 14, 2026 at 4:03 PM
Fri news: Novo's Wegovy pill struggles to break through market share ceiling. Karyopharm as company faces potential default next month. BMS bags first approval for myeloma CELMoD Zenbexus. Novartis wins UK court battle over Entresto patent. —https://bit.ly/3JeBlY5